Fate Therapeutics shares are trading higher. The company announced data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATE

0.00

Fate Therapeutics shares are trading higher. The company announced data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting